Six-Month Data From The SurModics (SRDX) Surveil Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company’s SurVeil®drug-coated balloon (DCB) was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances (VIVA) 2017 […]

Lombard Medical Announces Completion of Restructuring and Implementation of Strategic Plan to Achieve Profitability

OXFORDSHIRE, England–(BUSINESS WIRE)–Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced completion of a restructuring following the implementation of its new strategy to focus sales efforts in the UK, Japan and China, and reduce operating and manufacturing costs in order to […]

First Round Of Late-Breaking Endovascular Clinical Trial Results Announced At VIVA 17

LAS VEGAS, Sept. 12, 2017 /PRNewswire-USNewswire/ — VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the first five of 20 highly anticipated late-breaking clinical trial results on Tuesday morning at VIVA 17, hosted at the Wynn Las Vegas. Below are highlights […]

Teleflex Inc. (TFX) To Present The Peripheral Intervention Product Portfolio From Its New Subsidiary, Vascular Solutions At The Annual Meeting And Postgraduate Course Of The Cardiovascular And Interventional Radiological Society Of Europe (CIRSE) 2017

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, will showcase the product portfolio recently acquired from its new subsidiary, Vascular Solutions, as well as its Arrow® Hemodialysis, Oncology and Peripheral Intervention Solutions at the CIRSE Congress being held in […]

PQ Bypass Reports Positive Results For The Novel DETOUR System In Patients With Tough To Treat Long Blockages In The Femoropopliteal Artery

SUNNYVALE, Calif.–(BUSINESS WIRE)–A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ DETOUR System for treating long-segment (>25 cm) blockages in the femoropopliteal artery. The data were presented as a late breaking clinical trial session today at Vascular InterVentional Advances (VIVA 17) […]

Medtronic (MDT) IN.PACT Admiral DCB Global Two Year Data And IN.PACT SFA Four Year Data Presented In VIVA Late Breaking Clinical Trials

DUBLIN and LAS VEGAS – September 12, 2017 – Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical cohort of the IN.PACT Global Study and four-year […]

Gecko Biomedical receives CE Mark Approval for SETALUM™ Sealant

Approval of CE Mark paves the way for application expansion and the exploration of new therapeutic areas for ground-breaking surgical solutions. Paris, France, September 11, 2017 – Gecko Biomedical (“Gecko”), a medical device company developing innovative polymers to support tissue reconstruction, announced today that it has received CE Mark approval […]

Vasorum Launches Celt ACD® Second Generation Vascular Closure Device in the USA

DUBLIN, Ireland, September 12, 2017 /PRNewswire/ — Vasorum Ltd, following FDA approval of its PMA supplement, the developer and manufacturer of the novel Celt ACD®vascular closure device has added a 7F sized Celt ACD® device to its Celt ACD® 6F and Celt ACD® 5F size range in the USA. Celt ACD® is indicated for arterial puncture closure in […]

Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. (“JLL”) pertaining to the development and distribution of novel endovascular […]